Skip to main content

SIMPLAAFY Clinical Trial

Active, not recruiting · Not applicable · NCT06521463

Conditions: Atrial Fibrillation, Stroke, Bleeding

At a glance

Research payments reported, 2025
$6.8M
U.S. investigators named
86
Sites paid
85
Planned or actual enrollment
1,857

About the trial

Sponsor
Boston Scientific Corporation
Tested
WATCHMAN FLX Pro LAAC Device (device)
Dates
Started 2024-10-01; completion 2027-01
Results posted
Not yet

The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.

From ClinicalTrials.gov, last updated 2026-10-13. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $6.8M in research payments for this study in 2025 (780 payments).

Products named: Watchman Access System

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.